Australia Pharmaceuticals Market Size, Share and Outlook - Growth Analysis Report and Forecast Trends (2026-2035)

Market Overview

The Australia pharmaceuticals market is being reshaped by price and access. One government payer sets most prices, a lower patient co-payment widens use, and global pricing pressure is making originator companies more selective about which products they bring to Australia.

Three forces are shaping the market: scale, with government PBS spending of AUD 19.1 billion in the year to June 2025; affordability, as the general co-payment fell to AUD 25 on 1 January 2026; and biologics, as biosimilar listings such as Sandoz's Afqlir from 1 February 2026 open competition in high-cost classes.

In November 2025 Health Minister Mark Butler warned that United States most-favoured-nation pricing could pressure governments to delist existing PBS medicines. In July 2026 Medicines Australia reported that only about a quarter of medicines launched globally in the past decade are PBS-listed.

Key Market Trends and Insights

• Large subsidised base: The Department of Health's PBS statistics show government expenditure of AUD 19.1 billion on 225.97 million subsidised prescriptions in the year to June 2025, with patients paying a further AUD 1.7 billion.
• Cheaper scripts from January 2026: The maximum general patient co-payment fell from AUD 31.60 to AUD 25 on 1 January 2026 across more than 900 medicines, at a budgeted cost of AUD 689.1 million.
• Slow access to new medicines: Medicines Australia said in July 2026 that about 25% of medicines launched globally in the past decade are PBS-listed, against 46% in the United Kingdom and 88% in the United States.
• Private demand for weight-loss drugs: Minister Butler said on 10 August 2026 that about 600,000 Australians buy weight-loss drugs privately, at a potential AUD 5,000 to AUD 6,000 a year, while PBS price talks stay stalled.

Australia Pharmaceuticals Market Size and Forecast

The market is moving from small-molecule originators towards biologics, biosimilars and specialty therapies, while generics hold the volume base and plasma-derived products and vaccines follow global demand cycles. Oncology leads in value, and cardiovascular and metabolic care advances quickest as obesity and diabetes treatments seek reimbursement. Community pharmacies dominate supply, yet online and mail-order channels gain share as private-pay prescribing spreads. New South Wales remains the largest region, and Queensland grows fastest on population inflow and new sterile manufacturing capacity. Price negotiation, biosimilar competition and local manufacturing investment point to a durable change in product mix rather than a cyclical uplift.

Key Takeaways: Australia Pharmaceuticals Market

A Government-Anchored Market Compounds Steadily

Revenue is on course to expand by about 63% across the decade, from AUD 27.00 billion in 2025 to AUD 43.98 billion in 2035 at a 5.0% CAGR. Government PBS spending of AUD 19.1 billion in the year to June 2025 gives suppliers a stable, predictable payer base.

Biologics and Metabolic Care Lead Growth

Originator small-molecule medicines hold the largest share, but Biologics and Biosimilars grow at an estimated 7.2% CAGR and Cardiovascular and Metabolic care at an estimated 6.6% CAGR through 2035. Wegovy's PBAC recommendation reported in January 2026 and Sandoz's February 2026 aflibercept listing show both forces at work.

Global Pricing Pressure Tests Access

Companies are weighing Australian prices against international reference points, and negotiations are becoming more public. Several supply decisions in 2026 show how a lower price can change which medicines are offered.

• Eli Lilly declined PBS listing of Mounjaro for type 2 diabetes in April 2026
• AstraZeneca planned to withdraw Zoladex 3.6mg from the PBS in November 2026 before agreeing to supply it free
• Minister Butler said in August 2026 that weight-loss drug price talks have not reached agreement

Australia Pharmaceuticals Market Report Summary

Key Insight

Biologics, obesity treatments and a lower patient co-payment lift value, while pricing pressure and slow listings temper growth. New South Wales leads, and Queensland grows fastest.

Key Trends in the Australia Pharmaceuticals Market

The Australia pharmaceuticals market is being reshaped by weight-loss drug pricing, slow access to new medicines, tougher listing negotiations and a lower patient co-payment.

August 2026 - Minister Butler Says Weight-Loss Drug Price Talks Have Stalled

• On 10 August 2026 Health Minister Mark Butler said about 600,000 Australians now buy weight-loss drugs privately.
• He said PBS advisers favoured a limited listing for patients with a BMI of 35 or higher and established heart disease, and that price agreement had not been reached.
• A narrow listing leaves most users paying privately, sustaining online supply.

July 2026 - Medicines Australia Reports Only a Quarter of New Medicines Are PBS-Listed

• Medicines Australia's Bitter Pill report, published on 20 July 2026, found 18 medicines available overseas but not in Australia.
• It said net investment in innovative medicines has fallen as a share of the health budget, and asked for timely delivery of the Health Technology Assessment review.
• Slower listings favour established generics and biosimilars over newly launched originators.

April 2026 - Eli Lilly Declines to List Mounjaro on the PBS for Type 2 Diabetes

• newsGP reported on 28 April 2026 that Eli Lilly rejected the price conditions proposed after the PBAC recommended listing in March 2026.
• Up to 450,000 Australians with type 2 diabetes could have been affected, and Lilly called the proposed price unviable.
• Tougher negotiations can delay metabolic therapies, leaving semaglutide and dulaglutide as the subsidised options.

January 2026 - General Patient Co-Payment Falls to AUD 25

• From 1 January 2026 the maximum general patient payment fell from AUD 31.60 to AUD 25 for more than 900 PBS medicines.
• The March 2025 Budget costed the measure at AUD 689.1 million, and the AUD 7.70 concession rate stays frozen until 2030.
• Lower patient costs support adherence and dispensing volumes in community pharmacies.

Key Insight

Weight-loss drug price talks, tougher listing negotiations and a lower patient co-payment shape demand, while slow access to new medicines remains the main constraint on uptake.

Recent Market Developments in the Australia Pharmaceuticals Market

Recent developments, presented from the most recent, show pharmacy-led growth, a planned withdrawal of a subsidised product, new generic partnerships and the delay of a vaccine business spin-off.

August 2026 - Sigma Healthcare Reports Revenue of AUD 10.8 Billion and 561 Chemist Warehouse Stores

• Sigma's full-year results of 27 August 2026 showed revenue up 15.5% to AUD 10.8 billion, the first full year since its merger with Chemist Warehouse.
• It added 24 Chemist Warehouse stores in Australia, reaching 561, and plans 13 more in Australia and 19 internationally in the first half.
• Scale in wholesale and pharmacy retail gives the group leverage over generic supply terms.

July 2026 - AstraZeneca Plans to Remove Zoladex 3.6mg from the PBS, Then Agrees to Free Supply

• newsGP reported on 20 July 2026 that AstraZeneca would stop PBS supply in November 2026, saying the PBS price was too low to sustain.
• After patient and GP advocacy it confirmed free supply from 1 November 2026, covering 92,191 dispensings in the 12 months to May 2026.
• Low-priced older oncology products can become supply risks under current PBS arrangements.

February 2026 - Arrotex and Pfizer Australia Partner on Enbrel Distribution

• Pharmacy Daily reported on 12 February 2026 that Arrotex will represent Pfizer's Enbrel (etanercept) in community pharmacy, hospital pharmacy and prescriber channels.
• It is the first Arrotex partnership with Pfizer and extends the generics supplier's platform to an originator biologic.
• Biologic brands are moving to generic-style distribution as biosimilar competition grows.

October 2025 - CSL Delays Seqirus Spin-Off as United States Vaccination Rates Fall

• On 27 October 2025 CSL shelved its plan to list the Seqirus influenza vaccine business on the ASX by June 2026.
• It cited United States volatility, expected northern hemisphere vaccination rates to drop about 12%, and cut revenue growth guidance to 2% to 3%.
• The delay keeps CSL focused on plasma and vaccine supply under pressure.

Key Insight

Biosimilar listings, generic partnerships and a planned withdrawal of one subsidised product show suppliers adjusting portfolios to Pharmaceutical Benefits Scheme pricing, while local manufacturing capacity expands.

Australia Pharmaceuticals Industry Segmentation

The Expert Market Research’s report on the Australia Pharmaceuticals Market offers a detailed analysis of the market based on the following segments.

Market Breakup by Product Type

• Originator Small-Molecule Medicines
• Generic Medicines
• Biologics and Biosimilars
• Plasma-Derived Products and Vaccines
• Others

Originator Small-Molecule Medicines lead on value, in our estimate, because patented oncology, cardiovascular and endocrine products carry the highest unit prices, with the March 2025 Budget adding AUD 1.8 billion of new and amended PBS listings. Generic Medicines hold the largest dispensing volume, and Arrotex's August 2025 Bayer oral contraceptive partnership shows suppliers extending beyond classic generics. Biologics and Biosimilars grow fastest at an estimated 7.2% CAGR through 2035, as Sandoz's Afqlir became the first PBS-listed aflibercept biosimilar on 1 February 2026. Plasma-Derived Products and Vaccines track global demand, with CSL's revenue down about 1% in August 2026.

Market Breakup by Therapeutic Area

• Oncology
• Cardiovascular and Metabolic
• Immunology and Inflammatory Diseases
• Neurology and Mental Health
• Others

Oncology leads in value, in our estimate, with AstraZeneca's Zoladex dispensed 92,191 times in the 12 months to May 2026 alone. Cardiovascular and Metabolic care grows fastest at an estimated 6.6% CAGR through 2035, as the PBAC recommended Wegovy for adults with heart disease and obesity in its November 2025 meeting and Eli Lilly declined to list Mounjaro in April 2026. Immunology and Inflammatory Diseases benefit from etanercept and ustekinumab biosimilars. Neurology and Mental Health includes two multiple sclerosis medicines under rapid review due by the end of 2026. Others include infectious disease, respiratory and rare conditions.

Market Breakup by Sales Channel

• Community Pharmacies
• Hospital Pharmacies
• Online and Mail-Order Pharmacies
• Others

Community Pharmacies lead, in our estimate, as most of the 225.97 million subsidised prescriptions in the year to June 2025 were dispensed there, and Sigma's 561 Chemist Warehouse stores at August 2026 show the scale of the leading network. Hospital Pharmacies supply infused cancer and immunology therapies and plasma products, and the Arrotex and Pfizer Enbrel partnership of February 2026 spans hospital pharmacy. Online and Mail-Order Pharmacies grow fastest at an estimated 8.4% CAGR through 2035, as about 600,000 Australians buy weight-loss drugs privately, according to Minister Butler in August 2026. Others cover dispensing from clinics, aged care and direct-to-patient supply.

Market Breakup by Region

• New South Wales
• Victoria
• Queensland
• Western Australia
• Others

New South Wales dominates, in our estimate, as the most populous state, with Vitex's AUD 250 million Eastern Creek plant opening in July 2026 and a AUD 96 million RNA facility at Macquarie University due in 2026. It grows at an estimated 4.7% CAGR through 2035 from a mature base. Victoria, the base of CSL and Arrotex, grows at 4.9% and held 30% of clinical trial sites in August 2026. Queensland is the fastest-growing region at an estimated 5.6%, as Southern RNA gained state funding in May 2026 for sterile fill and finish capacity. Western Australia grows at 5.3%, and Others, covering the remaining states and territories, at 5.1%.

Purchase the Regional Overview for USD 1099

If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.

Purchase the Regional Overview for USD 1099

If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.

Competitive Landscape in the Australia Pharmaceuticals Market

Competition combines global originators, local generic suppliers, a plasma and vaccine group and large pharmacy networks. Entry barriers include Therapeutic Goods Administration registration, PBS listing success, biosimilar timing, cold chain supply and pharmacy and hospital relationships.

CSL

CSL, headquartered in Melbourne, develops plasma-derived therapies through CSL Behring, influenza vaccines through Seqirus and iron and kidney products through Vifor. On 18 August 2026 it reported revenue of nearly USD 15.8 billion, down about 1%, and a net loss of almost USD 3 billion after USD 7.9 billion of impairment and restructuring costs. Gordon Naylor became interim chief executive in February 2026.

AstraZeneca

AstraZeneca, whose global headquarters is in Cambridge, United Kingdom, operates in Australia from Sydney and sells oncology, cardiovascular, respiratory and rare disease medicines. In July 2026 it said it would stop PBS supply of Zoladex 3.6mg in November, citing the PBS price, then confirmed free supply from 1 November 2026. The product was dispensed 92,191 times in the 12 months to May 2026.

Sandoz

Sandoz, the Swiss generics and biosimilars company headquartered in Basel, supplies Australian pharmacies and hospitals from its local operation. The Therapeutic Goods Administration approved its aflibercept biosimilars Afqlir and Enzeevu on 27 May 2025, and Afqlir became the first PBS-listed aflibercept biosimilar on 1 February 2026. Its Tyruko natalizumab biosimilar was also positioned for PBS listing from July 2025.

Arrotex Pharmaceuticals

Arrotex Pharmaceuticals, a Melbourne-based supplier, is described as Australia's largest generic pharmaceutical company by volume, selling prescription and consumer health products through community pharmacies. In August 2025 it partnered with Bayer Australia to market the Yaz and Yasmin oral contraceptives, and in February 2026 it began representing Pfizer's Enbrel across pharmacy, hospital and prescriber channels.

Other players operating in the Australia pharmaceuticals market include Pfizer Australia, Viatris, Sigma Healthcare, Eli Lilly Australia, and Sanofi, alongside regional distributors, specialty biotechnology sponsors, contract manufacturers and private-label suppliers supplying medicines to pharmacies, hospitals, clinics and online dispensers across Australia.

Key Insight

Competition rests on Pharmaceutical Benefits Scheme listing success, patent portfolios, biosimilar timing and pharmacy reach rather than price alone, while restructuring at the largest local group reshapes priorities.